Table 1.
Characteristics of the Study Population
| Characteristic | Overall | Arm A (Vorinostat + Tamoxifen) | Arm B (Vorinostat ) |
|---|---|---|---|
| Sex, number (%), female | 31 (100) | 21 (100) | 10 (100) |
| Age, median (Q1, Q3), years | 57 (53–60) | 57 (54–61) | 55 (51–59) |
| Race, number (%) | |||
| American Indian or Alaskan Native | 1 (3) | 1 (5) | 0 (0) |
| Black or African American | 18 (58) | 11 (52) | 7 (70) |
| White | 12 (39) | 8 (38) | 3 (30) |
| Ethnicity, number (%) | |||
| Hispanic/Latino | 6 (19) | 4 (19) | 2 (20) |
| Not Hispanic/Latino | 25 (81) | 17 (81) | 8 (80) |
| Years since antiretroviral therapy start, median Q1, Q3) | 7.5 (2.9–13.9) | 6.1 (2.4–13.9) | 9.4 (5.9–12.2) |
| Nadir CD4+ T-cell count, median (Q1, Q3), cells/mm3 | 232 (46–363) | 232 (10–363) | 261 (80–402) |
| Screening CD4+ T-cell count, median (Q1, Q3), cells/mm3 | 688 (536–854) | 688 (536–773) | 722 (566–1106) |
| Antiretroviral regimen, number (%) | |||
| Integrase inhibitor + NRTIs | 24 (77%) | 18 (86%) | 6 (60%) |
| NNRTI + NRTIs | 3 (10%) | 1 (5%) | 2 (20%) |
| Protease inhibitor + NRTIs | 1 (3%) | 1 (5%) | 0 (0%) |
| Other combination | 3 (10%) | 1 (5%) | 2 (20%) |
Abbreviations: NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; Q1, first quartile (25th percentile); Q3, third quartile (75th percentile).